生产企业：Eli Lilly
Retatrutide (informally 'reta') is an investigational triple-agonist synthetic peptide developed by Eli Lilly that activates the GLP-1, GIP and glucagon receptors, being studied for weight loss/obesity. It is not yet approved by regulators such as the MHRA; Phase 3 trials are ongoing and Eli Lilly plans to file for regulatory approval in the first quarter of 2027. Unapproved supplies are sold illegally online, labelled 'for research use only' or as 'research chemicals'.
Retatrutide (informally 'reta') is an investigational triple-agonist synthetic peptide developed by Eli Lilly that activates the GLP-1, GIP and glucagon receptors, being studied for weight loss/obesity. It is not yet approved by regulators such as the MHRA; Phase 3 trials are ongoing and Eli Lilly plans to file for regulatory approval in the first quarter of 2027. Unapproved supplies are sold illegally online, labelled 'for research use only' or as 'research chemicals'.
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
